Friday, February 25, 2011

Allergan paid $600 million for illegally marketing Botox


Continuing my series highlighting the spate of huge off-label marketing cases, last year Allergan agreed to plead guilty to a misdemeanor and pay a $375 million fine and $225 million in civil penalties, all for pushing Botox for off-label uses such as headache, pain and cerebral palsy treatment.

Click here for the DoJ press release.
Click here for the Wall Street Journal story.
Below is the qui tam complaint.  
Allergan FCA Complaint                                                            

No comments:

Post a Comment